URGN – UroGen Pharma Ltd.
URGN — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
21.61
Margin Of Safety %
Put/Call OI Ratio
0.57
EPS Next Q Diff
0.17
EPS Last/This Y
2.02
EPS This/Next Y
2.09
Price
18.06
Target Price
35.62
Analyst Recom
1.25
Performance Q
-18.53
Upside
-723.1%
Beta
1.48
Ticker: URGN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | URGN | 19.95 | 0.89 | 0.00 | 6363 |
| 2026-03-10 | URGN | 19.42 | 0.80 | 0.50 | 6771 |
| 2026-03-11 | URGN | 18.84 | 0.80 | 0.17 | 6774 |
| 2026-03-12 | URGN | 18.81 | 0.80 | 0.12 | 6780 |
| 2026-03-13 | URGN | 18.79 | 0.80 | 0.10 | 6780 |
| 2026-03-17 | URGN | 18.59 | 0.80 | 1.74 | 6916 |
| 2026-03-18 | URGN | 18.48 | 0.81 | 1.43 | 7011 |
| 2026-03-19 | URGN | 18.57 | 0.72 | 0.00 | 6680 |
| 2026-03-20 | URGN | 17.64 | 0.71 | 0.18 | 6653 |
| 2026-03-23 | URGN | 17.28 | 0.48 | 0.18 | 5305 |
| 2026-03-24 | URGN | 17.64 | 0.47 | 0.08 | 5450 |
| 2026-03-25 | URGN | 18.1 | 0.46 | 0.08 | 5527 |
| 2026-03-26 | URGN | 17.92 | 0.45 | 1.87 | 5640 |
| 2026-03-27 | URGN | 17.16 | 0.48 | 65.83 | 5809 |
| 2026-03-30 | URGN | 16.97 | 0.57 | 0.05 | 6186 |
| 2026-03-31 | URGN | 17.98 | 0.59 | 0.20 | 6099 |
| 2026-04-01 | URGN | 18.96 | 0.59 | 0.04 | 6129 |
| 2026-04-02 | URGN | 18.87 | 0.58 | 2.50 | 6196 |
| 2026-04-06 | URGN | 18.61 | 0.57 | 0.05 | 6212 |
| 2026-04-07 | URGN | 18.03 | 0.57 | 1.60 | 6261 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | URGN | 19.97 | 45.9 | - | -1.18 |
| 2026-03-10 | URGN | 19.42 | 45.9 | - | -1.18 |
| 2026-03-11 | URGN | 18.89 | 45.9 | - | -1.18 |
| 2026-03-12 | URGN | 18.77 | 45.9 | - | -1.18 |
| 2026-03-13 | URGN | 18.43 | 45.5 | - | -1.17 |
| 2026-03-17 | URGN | 18.57 | 45.5 | - | -1.17 |
| 2026-03-18 | URGN | 18.50 | 45.5 | - | -1.17 |
| 2026-03-19 | URGN | 18.61 | 45.5 | - | -1.17 |
| 2026-03-20 | URGN | 17.62 | 45.5 | - | -1.17 |
| 2026-03-23 | URGN | 17.30 | 45.5 | - | -1.17 |
| 2026-03-24 | URGN | 17.66 | 45.5 | - | -1.17 |
| 2026-03-25 | URGN | 18.12 | 45.5 | - | -1.17 |
| 2026-03-26 | URGN | 17.91 | 45.5 | - | -1.17 |
| 2026-03-27 | URGN | 17.14 | 45.5 | - | -1.17 |
| 2026-03-30 | URGN | 16.99 | 45.5 | - | -1.17 |
| 2026-03-31 | URGN | 17.97 | 45.5 | - | -1.17 |
| 2026-04-01 | URGN | 18.93 | 45.5 | - | -1.17 |
| 2026-04-02 | URGN | 18.87 | 45.5 | - | -1.17 |
| 2026-04-06 | URGN | 18.61 | 45.5 | - | -1.17 |
| 2026-04-07 | URGN | 18.06 | 45.5 | - | -1.17 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | URGN | -0.34 | 3.98 | 23.38 |
| 2026-03-10 | URGN | -0.31 | 3.98 | 23.38 |
| 2026-03-11 | URGN | -0.31 | 3.98 | 20.08 |
| 2026-03-12 | URGN | -0.31 | 3.98 | 20.08 |
| 2026-03-13 | URGN | -0.31 | 3.98 | 20.08 |
| 2026-03-17 | URGN | -0.31 | 3.96 | 20.08 |
| 2026-03-18 | URGN | -0.31 | 3.96 | 20.08 |
| 2026-03-19 | URGN | -0.31 | 3.96 | 20.08 |
| 2026-03-20 | URGN | -0.31 | 3.96 | 20.08 |
| 2026-03-23 | URGN | -0.31 | 3.96 | 20.08 |
| 2026-03-24 | URGN | -0.31 | 3.96 | 20.08 |
| 2026-03-25 | URGN | -0.31 | 3.96 | 21.61 |
| 2026-03-26 | URGN | -0.31 | 3.96 | 21.61 |
| 2026-03-27 | URGN | -0.31 | 3.96 | 21.61 |
| 2026-03-30 | URGN | -0.31 | 3.96 | 21.61 |
| 2026-03-31 | URGN | -0.31 | 3.96 | 21.61 |
| 2026-04-01 | URGN | -0.31 | 3.96 | 21.61 |
| 2026-04-02 | URGN | -0.31 | 3.96 | 21.61 |
| 2026-04-06 | URGN | -0.31 | 3.91 | 21.61 |
| 2026-04-07 | URGN | -0.31 | 3.91 | 21.61 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.54
Avg. EPS Est. Current Quarter
-0.5
Avg. EPS Est. Next Quarter
-0.37
Insider Transactions
-0.31
Institutional Transactions
3.91
Beta
1.48
Average Sales Estimate Current Quarter
44
Average Sales Estimate Next Quarter
56
Fair Value
Quality Score
24
Growth Score
51
Sentiment Score
89
Actual DrawDown %
39.8
Max Drawdown 5-Year %
-82.6
Target Price
35.62
P/E
Forward P/E
19.65
PEG
P/S
7.99
P/B
P/Free Cash Flow
EPS
-3.21
Average EPS Est. Cur. Y
-1.17
EPS Next Y. (Est.)
0.92
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-139.81
Relative Volume
0.65
Return on Equity vs Sector %
118.1
Return on Equity vs Industry %
134.6
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.2
EBIT Estimation
◆
URGN
Healthcare
$18.03
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
44.6
Range 1M
33.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
63.4%
EPS NY
178.5%
52W%
55%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+84% upside
Upside
+84%
Quality
24
UroGen Pharma Ltd.Sector: Healthcare
Industry: Biotechnology
Employees: 291
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
URGN
Latest News
—
Caricamento notizie per URGN…
stock quote shares URGN – UroGen Pharma Ltd. Stock Price stock today
news today URGN – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025
marketwatch URGN – UroGen Pharma Ltd. yahoo finance google finance
stock history URGN – UroGen Pharma Ltd. invest stock market
stock prices URGN premarket after hours
ticker URGN fair value insiders trading